Read More Healthcare Industry News HLN share price firms as Sensodyne and Centrum drive Haleon’s 2026 organic growth recovery Sensodyne grows 8%. Centrum targets GLP-1 users. The £500m buyback erases shares at sub-340p. Haleon's recovery hinges on Q2 cold and flu normalising. bySrinathMay 16, 2026